VX-581 / Vertex - LARVOL DELTA

A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=128 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=152 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Nov 2026 ➔ Jul 2027 | Trial primary completion date: Nov 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases